Description
Kobe 2602 is an inhibitor of Ras that exhibits anticancer chemotherapeutic activities. In vitro, this compound inhibits cell growth and induces apoptosis and in vivo, it decreases tumor growth.
| Product Unit Size | Cost | Quantity | Stock |
|---|
Kobe 2602 is an inhibitor of Ras that exhibits anticancer chemotherapeutic activities. In vitro, this compound inhibits cell growth and induces apoptosis and in vivo, it decreases tumor growth.
| Cas No. | 454453-49-7 |
|---|---|
| Purity | ≥98% |
| Formula | C14H9F4N5O4S |
| Formula Wt. | 419.31 |
| Chemical Name | 2-[2,6-Dinitro-4-(trifluoromethyl)phenyl]-N-(4-fluorophenyl)hydrazinecarbothioamide |
| IUPAC Name | 2-[2,6-Dinitro-4-(trifluoromethyl)phenyl]-N-(4-fluorophenyl)hydrazinecarbothioamide |
| Synonym | 2-[2,6-Dinitro-4-(trifluoromethyl)phenyl]-N-(4-fluorophenyl)hydrazinecarbothioamide |
| Solubility | DMSO: 15 mg/mL |
| Appearance | Light yellow solid |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Shima F, Yoshikawa Y, Ye M, et al. In silico discovery of small-molecule Ras inhibitors that display antitumor activity by blocking the Ras-effector interaction. Proc Natl Acad Sci U S A. 2013 May 14;110(20):8182-7. PMID: 23630290.
Shima F, Yoshikawa Y, Matsumoto S, et al. Discovery of small-molecule Ras inhibitors that display antitumor activity by interfering with Ras·GTP-effector interaction. Enzymes. 2013;34 Pt. B:1-23. PMID: 25034098.
Potent and selective inhibitor
Fluoroquinolone; topoisomerase IV and bacterial...
EGFR (WT, T790M) inhibitor.
EGFR inhibitor.
Purine derivative; CDK inhibitor.
Synthesis impurity
Polyphenol found in species of Solanum and Magn...
Peptide, casein fragment.
Peptide; PAR1 agonist.
Alkaloid found in Fabaceae family plants; α3β...
Polyether pyrrole, divalent cation ionophore.
Sulfonamide; PABA inhibitor.
Side chain attached to various taxanes.
Peptide used to measure in vitro calcineurin ac...
Highly selective inhibitor
Tocopherol analog
Steroidal alkaloid found in Fritillaria; M2 mAC...
5-HT3 antagonist.
Aurora kinase A inhibitor
Dual RAF/EGFR inhibitor.